Discover Our Organic Mineral Salts as APIs
![](/46/pdcnewsitem/12/08/33/784x590%20news%20header%20-%202023-05-10T162530.711.png)
Discover the range of organic mineral salts that serve as Active Pharmaceutical Ingredients available from Dr. Paul Lohmann®.
Due to their favorable bioavailability, organic Mineral Salts frequently serve as a source of cations to counteract mineral deficiencies. Dr. Paul Lohmann® produces a broad portfolio of high-quality organic Mineral Salts - based on Calcium, Copper, Iron, Magnesium, Manganese, Potassium and Zinc - which are ideally suited as active pharmaceutical ingredients (API) and are available including comprehensive API documentation.
Organic Ferrous Bisglycinate against Iron Deficiency Anemia
Dr. Paul Lohmann® is the world’s first manufacturer of Ferrous Bisglycinate as an active pharmaceutical ingredient (API), which is available with a DMF/ASMF for the registration of a drug at health authorities. The glycine chelate structure of the Ferrous Bisglycinate protects the highly reactive Iron from redox reactions in the gastrointestinal tract and thus prevents unpleasant side effects such as epigastric pain, nausea, vomiting and abdominal cramps [1].
Highly bioavailable Zinc and Potassium Salts
Organic Potassium and Zinc Salts with beneficial bioavailability are ideal sources of Minerals to counteract deficiency symptoms, e.g.:
- Potassium Gluconate is a readily water-soluble source of Potassium and is used to treat hypokalemia and associated symptoms such as hypertension, as well as respiratory and digestive problems.
- Zinc Gluconate and Zinc Citrate are excellent for replenishing Zinc levels in the body, which helps strengthen the immune system and promote wound healing.
Experience meets Innovation
With our expertise in the chemical and physical modification of Mineral Salts combined with our customer-oriented corporate philosophy, we are the ideal partner to turn your ideas into reality.
For more information, please contact us at [email protected] or visit our website here.
[1] Ferrari, P., et al. Treatment of mild non-chemotherapy-induced iron deficiency anemia in cancer patients: comparison between oral ferrous bisglycinate chelate and ferrous sulfate. Biomedicine & Pharmacotherapy, 2012, 66(6), 414–418.
Related News
-
News On track at Pharmapack 2024 - The Track Sponsor interview: Gerresheimer
January 2024 brings both a new year and Europe’s leading packaging and drug delivery event. Gathering the world’s experts in pharmaceutical packaging together in Paris, France, Pharmapack 2024 offers exciting opportunities to learn and coll... -
News The Patient-Centric Synergy of Pharmaceutical CDMO and CRO Collaborations
Pharmaceutical collaborations are nothing new to the industry. Increasingly complex drug development programs, calls for supply chain resiliency, and the involvement of all key stakeholders throughout a drug’s development lifecycle are pushing co... -
Sponsored Content CPHI Podcast Series: Ursatec – celebrating 30 years of pioneering preservative free
In the latest episode of the CPHI Podcast Series, Digital Editor Lucy Chard spoke with Dominik Rocchi of Ursatec. -
News Seqens Group Expands CDMO Offerings to Include CRDO
Meet with Seqens team members at CPHi, April 25-27, 2023 to learn how we have extended services to rapidly and sustainably advance drug development. VISIT CPHI Booth 441 -
News CDMO - Health is a Joint Project: Connect to Frankfurt on-demand
In this Connect to Frankfurt session, Emanuele Agnese, Business Development Manager and Pietro Allegrini, R&D Director at Indena, present the ways in which a reliable manufacturing partner in the pursuit of better health outcomes for patients and pharm... -
News Streamlined Development for Efficient Production of Bispecific Molecules: Connect to Frankfurt on-demand
In this Connect to Frankfurt session, Séverine Fagète, VP, Cell Line Development Services at Selexis (Geneva, Switzerland), and Brandon Brino (Durham, USA), Process Development Scientist and Group Leader at KBI Biopharma, present an overv... -
News MDR – How to collect post-market clinical follow-up data (PMCF): Connect to Frankfurt on-demand
In this Connect to Frankfurt session, Philipp Annecke, Junior Key Account Manager and Heinrich Martens, VP Regulatory Affairs of Fresenius Kabi (Bad Homburg, Germany) present guidances from the Medical Devices Regulation on clinical data evaluatio... -
News Packaging and Drug Delivery Trends - 5 key learning points for 2022
During the recent CPHI Webinar Packaging & Drug Delivery Trends for 2022 sponsored by Portal Instruments, experts discussed the crucial factors to consider during the development process, such as digitalisation, sustainability and a shift towards self-...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance